Literature DB >> 17944989

The contribution of amino acid residues 1508-1515 of factor V to light chain generation.

E Erdogan1, M A Bukys, M Kalafatis.   

Abstract

BACKGROUND: Factor (F) V is activated by alpha-thrombin following cleavages at Arg(709), Arg(1,018) and Arg(1,545). Amino acid region 1,490-1,520 of FV is essential for procofactor activation. AIM: To ascertain which amino acid residues from this region are important for light chain formation and procofactor activation, site-directed mutagenesis was used to create recombinant FV molecules missing amino acid 1,508-1,510 (FV(Delta1,508-1,510)) and 1,508-1,515 (FV(Delta1508-1515)). We have also created recombinant FV molecules with mutations (1508)DDY(1510)-->AAF (FV(AAF)), (1514)DY(1515)-->AF (FV(AF)) and Y(1510)-->F (FV(Y1510F)). METHODS AND
RESULTS: The recombinant mutant molecules were expressed and purified to homogeneity. The clotting activities of all clotting recombinant mutant FV molecules were tested in a two-stage assay following activation by alpha-thrombin and were found to be impaired compared with the clotting activity observed with wild-type recombinant FV or plasma-derived FV, with the exception of FV(Y1510F), which had normal clotting activity. Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with monoclonal antibodies to FV demonstrated that incubation of 100 nm recombinant wild-type or plasma-derived FV with 1 nmalpha-thrombin for 5 min was sufficient to generate heavy and light chains and completely activate the procofactor. In contrast, similar experimental conditions were ineffective in fully activating the two deletion mutant molecules as well as FVa(AAF) and FVa(AF), resulting in accumulation of a M(r) 220,000 fragment representing amino acids 1,019-2,195.
CONCLUSION: Our data demonstrate that amino acid residues 1,508-1,515 of FV are required for efficient cleavage by alpha-thrombin and light chain formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944989     DOI: 10.1111/j.1538-7836.2007.02803.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C.

Authors:  Melissa A Barhoover; Michael Kalafatis
Journal:  Blood Coagul Fibrinolysis       Date:  2011-06       Impact factor: 1.276

2.  Contribution of amino acid region 659-663 of Factor Va heavy chain to the activity of factor Xa within prothrombinase .

Authors:  Jamila Hirbawi; John L Vaughn; Michael A Bukys; Hans L Vos; Michael Kalafatis
Journal:  Biochemistry       Date:  2010-09-13       Impact factor: 3.162

3.  Role of the acidic hirudin-like COOH-terminal amino acid region of factor Va heavy chain in the enhanced function of prothrombinase.

Authors:  Jamila Hirbawi; Michael A Bukys; Melissa A Barhoover; Evrim Erdogan; Michael Kalafatis
Journal:  Biochemistry       Date:  2008-07-01       Impact factor: 3.162

4.  Contribution of amino acid region 334-335 from factor Va heavy chain to the catalytic efficiency of prothrombinase.

Authors:  Melissa A Barhoover; Tivadar Orban; Daniel O Beck; Michael A Bukys; Michael Kalafatis
Journal:  Biochemistry       Date:  2008-06-07       Impact factor: 3.162

5.  Amino acid region 1000-1008 of factor V is a dynamic regulator for the emergence of procoagulant activity.

Authors:  Joesph R Wiencek; Mahesheema Na; Jamila Hirbawi; Michael Kalafatis
Journal:  J Biol Chem       Date:  2013-10-31       Impact factor: 5.157

6.  Cooperative regulation of the activity of factor Xa within prothrombinase by discrete amino acid regions from factor Va heavy chain.

Authors:  Melissa A Barhoover; Tivadar Orban; Michael A Bukys; Michael Kalafatis
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

7.  Novel genes and mutations in patients affected by recurrent pregnancy loss.

Authors:  Paula Quintero-Ronderos; Eric Mercier; Michiko Fukuda; Ronald González; Carlos Fernando Suárez; Manuel Alfonso Patarroyo; Daniel Vaiman; Jean-Christophe Gris; Paul Laissue
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.